Articles related to FOOD ALLERGIES

Food allergies affect 33 million Americans, with 150 deaths annually from food-related allergic reactions in the US, emphasizing the critical need for stringent allergen management in public dining establishments.

Recent findings suggest that a slow up-dosing strategy in peanut oral immunotherapy for young children may offer a safer and more effective approach to managing peanut allergies.

Apple oral immunotherapy allowed patients to tolerate an entire apple after just 39 days on average, with potential cross-tolerance to other Rosaceae fruits.

In a stark reminder of the vulnerabilities that even healthcare professionals face, the tragic death of Dr. Kanokporn Tangsuan due to an allergic reaction at a Disney World restaurant underscores the critical importance of allergen awareness and self-care among physicians.

In a recent clinical trial, omalizumab demonstrated a significant increase in the threshold for allergic reactions to multiple food allergens in children and adolescents, suggesting its potential as a viable treatment option beyond current therapies. This study opens new avenues for the management of food allergies, providing hope for enhanced quality of life for affected individuals.

A phase 3, multicenter, double-blind, randomized, placebo-controlled trial was conducted to evaluate the efficacy and safety of epicutaneous immunotherapy with a peanut patch in children aged 1 to 3 years with peanut allergy. No approved treatment for peanut allergy exists for children under 4 years old. Participants with confirmed peanut allergy were assigned to either receive the peanut patch or a placebo daily for 12 months. The primary endpoint was the treatment response measured by the eliciting dose of peanut protein at 12 months. The trial showed that 67.0% of children in the intervention group demonstrated a treatment response compared to 33.5% in the placebo group. Adverse events occurred in both groups, with serious adverse events and anaphylaxis observed more frequently in the intervention group. However, serious treatment-related adverse events were rare. In conclusion, this trial demonstrated that epicutaneous immunotherapy with a peanut patch for 12 months was more effective than placebo in desensitizing children aged 1 to 3 years with peanut allergy and increasing their tolerance to peanut protein. Although adverse events were observed in both groups, serious treatment-related adverse events were uncommon. These findings suggest that epicutaneous immunotherapy may be a potential treatment option for young children with […]